leisure time -WSS

leisure time

author：focus 2025-09-02 08:20:59 - browse：1

Illumina said Monday afternoon that its board of directors had approved a spin-off of its cancer test subsidiary Grail, signaling that a nearly four-year-long, $8 billion saga will finally draw to a close this month.

Shares in the newly independent Grail are expected to be distributed on June 24, Illumina said in a statement. Illumina will retain a 14.5% stake in the company, which will trade under the ticker $GRAL.

It’s the second time Illumina has spun off Grail, which initially began as a unit within the DNA sequencing giant in 2015. Illumina turned it into an independent company the following year but then agreed to reacquire it for $8 billion in September 2020.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： A revolution in caring for preterm infants

WSS

Readout LOUD podcast: Merger Mondays, Ozempic panic

Massive project maps cells in human brain in unprecedented detail

How digital tools helped lower hypertension in marginalized patients

Vaccine advisory panel ACIP left half staffed by HHS

There’s no way to know how good AI health technologies are

Nick Jonas talks about managing diabetes along with his career

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

DIEP, the 'gold standard' of breast reconstruction, is under threat

What should King Charles tell the public about his cancer?

Cancer drug shortages should be causing more outrage

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

Hepatitis C has a cure — but many Americans still lack access to it

Gilead might be held responsible for not developing a drug

Hepatitis C has a cure — but many Americans still lack access to it

Peter Marks talks Operation Warp Speed for Rare Diseases

The cancer drug shortage isn’t new — and neither are the solutions

Industry veterans launch new biotech VC with $310M

hotspot

To avoid data mishandling cases, universities eye AI and other tools

Peter Marks talks Operation Warp Speed for Rare Diseases

STAT Readout Newsletter: Today in biotech, life science news

Robert F. Kennedy is pitching centrism on health, even on abortion

Researchers CRISPR chickens in bid to protect them from bird flu

Wellcome Trust names Røttingen as its new CEO

Wikipedia

focus

leisure time

explore